Sumit K. Chanda

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

This paper identifies a small molecule, M4, that inhibits influenza A and B replication by targeting the host protein STARD7, preventing vRNP nuclear export and demonstrating synergistic antiviral effects with baloxavir in mice.

This study shows that HIV-1 capsid binding remodels PQBP1 conformation to enable cGAS recruitment, linking capsid recognition to innate immune activation.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This study uses a high-diversity barcoded HIV library to analyze viral expression and fate determination at the single-cell level, revealing splicing isoforms and translation efficiency.

This study identifies critical human host factors involved in SARS-CoV-2 multicycle replication through a genome-scale siRNA screen and validates potential antiviral targets.

The paper predicts anti-SARS-CoV-2 targets by identifying synthetic lethal partners of host genes altered during infection, validated through CRISPR-Cas9 screens and siRNA experiments.

The paper identifies a two-factor authentication mechanism used by the innate immune system to detect low-abundance HIV-1 DNA through PQBP1-mediated capsid recognition and cGAS recruitment.

The paper uses genome-scale metabolic modeling to identify SARS-CoV-2-induced metabolic changes and predict antiviral targets validated through drug and genetic screens.

SARS-CoV-2 infects and kills neural cells in iPSC-derived human brain organoids and impairs synaptogenesis; the approved antiviral sofosbuvir is reported to reverse both effects.